Estimating the impact of control measures to prevent outbreaks of COVID-19 associated with air travel into a COVID-19-free country.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 05 2021
Historique:
received: 26 06 2020
accepted: 28 04 2021
entrez: 25 5 2021
pubmed: 26 5 2021
medline: 3 6 2021
Statut: epublish

Résumé

We aimed to estimate the risk of COVID-19 outbreaks associated with air travel to a COVID-19-free country [New Zealand (NZ)]. A stochastic version of the SEIR model CovidSIM v1.1, designed specifically for COVID-19 was utilised. We first considered historical data for Australia before it eliminated COVID-19 (equivalent to an outbreak generating 74 new cases/day) and one flight per day to NZ with no interventions in place. This gave a median time to an outbreak of 0.2 years (95% range of simulation results: 3 days to 1.1 years) or a mean of 110 flights per outbreak. However, the combined use of a pre-flight PCR test of saliva, three subsequent PCR tests (on days 1, 3 and 12 in NZ), and various other interventions (mask use and contact tracing) reduced this risk to one outbreak after a median of 1.5 years (20 days to 8.1 years). A pre-flight test plus 14 days quarantine was an even more effective strategy (4.9 years; 2,594 flights). For a much lower prevalence (representing only two new community cases per week in the whole of Australia), the annual risk of an outbreak with no interventions was 1.2% and had a median time to an outbreak of 56 years. In contrast the risks associated with travellers from Japan and the United States was very much higher and would need quarantine or other restrictions. Collectively, these results suggest that multi-layered interventions can markedly reduce the risk of importing the pandemic virus via air travel into a COVID-19-free nation. For some low-risk source countries, there is the potential to replace 14-day quarantine with alternative interventions. However, all approaches require public and policy deliberation about acceptable risks, and continuous careful management and evaluation.

Identifiants

pubmed: 34031465
doi: 10.1038/s41598-021-89807-y
pii: 10.1038/s41598-021-89807-y
pmc: PMC8144219
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10766

Subventions

Organisme : Health Research Council of New Zealand
ID : 16/443
Organisme : Health Research Council of New Zealand
ID : 20/1066

Commentaires et corrections

Type : CommentIn

Références

Sci Rep. 2021 Feb 24;11(1):4500
pubmed: 33627730
Dtsch Arztebl Int. 2021 Feb 5;118(5):59-65
pubmed: 33785117
Med J Aust. 2021 Oct 4;215(7):320-324
pubmed: 34472122
N Z Med J. 2020 Oct 30;133(1524):28-39
pubmed: 33119568
Am J Infect Control. 2021 Jan;49(1):21-29
pubmed: 32659413
N Z Med J. 2021 Feb 5;134(1529):26-38
pubmed: 33582705
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
Cochrane Database Syst Rev. 2020 Oct 5;10:CD013717
pubmed: 33502002
BMJ. 2020 Dec 22;371:m4907
pubmed: 33561814
Lancet Infect Dis. 2021 Jul;21(7):929-938
pubmed: 33765417
J Travel Med. 2020 Dec 23;27(8):
pubmed: 32975554

Auteurs

Nick Wilson (N)

BODE3 Programme, University of Otago, Wellington, New Zealand. nick.wilson@otago.ac.nz.
HEIRU, University of Otago, Wellington, New Zealand. nick.wilson@otago.ac.nz.

Michael G Baker (MG)

HEIRU, University of Otago, Wellington, New Zealand.

Tony Blakely (T)

Population Interventions Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.

Martin Eichner (M)

Epimos GmbH, Dußlingen, Germany.
Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH